Nucelion Therapeutics, a specialised cell and gene therapy CRDMO, and VeGen Bio, a precision oncology company, have entered into a strategic partnership for the technology transfer, clinical manufacturing, and commercialisation of innovative cell therapies in India.
Under the agreement, Nucelion, a wholly owned subsidiary of Bharat Biotech, will serve as the technology transfer and clinical- and commercial-stage manufacturing partner for VeGen Bio’s lead candidate, VL-2511, a first-in-class dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma into its single-site GMP manufacturing facility, designed to meet CDSCO, US FDA, and EMA regulatory standards.
“This partnership combines complementary strengths, providing VeGen Bio with a pathway to technology transfer, manufacturing, and pipeline expansion, while enabling our CDMO partner to establish and grow its cell therapy manufacturing capabilities,’’ Prashant Bhavar, Director, VeGen Bio, said.
The companies will also focus on process optimisation, manufacturing yields and operational efficiency to improve production economics, with the aim of reducing manufacturing costs and improving access to advanced cell therapies in India.